Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TGR BioSciences is an Australian life sciences company specializing in the development of innovative cell-based assay technologies for drug discovery. The company is best known for its proprietary CaptSure technology, which simplifies ELISA and other immunoassay formats by enabling one-wash, high-sensitivity detection of proteins. Their product portfolio includes the SureFire and SureFire Ultra assays, which are widely used for monitoring cell signaling pathways, particularly phosphoprotein targets. TGR's technologies are integrated into high-throughput screening workflows by major pharmaceutical companies and research institutions globally. In 2018, the company was acquired by Abcam to enhance its multiplexing and assay development capabilities.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on TGR BioSciences.